Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists

Traditionally tumors were classified based on anatomic location but now specific genetic mutations in cancers are leading to treatment of tumors with molecular targeted therapies. This has led to a paradigm shift in the classification and treatment of cancer. Tumors treated with molecular targeted therapies often show morphological changes rather than change in size and are associated with class specific and drug specific toxicities, different from those encountered with conventional chemotherapeutic agents. It is important for the radiologists to be familiar with the new cancer classification and the various treatment strategies employed, in order to effectively communicate and participate in the multi-disciplinary care. In this paper we will focus on lung cancer as a prototype of the new molecular classification.

• Publication year

  2017

• Venue

  Korean Journal of Radiology

• Publication date

  2017-01-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.3348/kjr.2017.18.1.6PMID 28096714PMCID 5240478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.

  2016cited by this paper
• CT Features of Epidermal Growth Factor Receptor–Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma

  2016cited by this paper
• The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

  2015cited by this paper
• Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

  2015cited by this paper
• Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan

  2015cited by this paper
• Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

  2015cited by this paper
• Current and future treatment of anaplastic lymphoma kinase-rearranged cancer.

  2015cited by this paper
• Complex renal cysts associated with crizotinib treatment

  2015cited by this paper
• Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.

  2015cited by this paper
• The prognosis of hepatocellular carcinoma after curative hepatectomy in young patients

  2015cited by this paper
• Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR

  2015cited by this paper
• Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement

  2015cited by this paper
• A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer

  2015cited by this paper
• Squamous Cell Carcinoma of the Vulva: A Subclassification of 97 Cases by Clinicopathologic, Immunohistochemical, and Molecular Features (p16, p53, and EGFR)

  2015influential reference
• Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

  2014cited by this paper
• Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.

  2014cited by this paper
• State of the art: Response assessment in lung cancer in the era of genomic medicine.

  2014cited by this paper
• ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.

  2014cited by this paper
• Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

  2014cited by this paper
• Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

  2013cited by this paper
• Personalizing extent of breast cancer surgery according to molecular subtypes.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.

  2013cited by this paper
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  2013influential reference
• The genetic landscape of high-risk neuroblastoma

  2013cited by this paper
• Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.

  2012cited by this paper
• Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer

  2012cited by this paper
• Inhibitors of the anaplastic lymphoma kinase

  2012cited by this paper
• Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.

  2012cited by this paper
• Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients.

  2012cited by this paper
• Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).

  2012cited by this paper
• Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

  2012cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

  2011cited by this paper
• Metastatic behavior of breast cancer subtypes.

  2010cited by this paper
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

  2010cited by this paper
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

  2010influential reference
• Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification

  2010cited by this paper
• Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

  2010influential reference
• Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology.

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009cited by this paper
• Identification of ALK as a major familial neuroblastoma predisposition gene

  2008cited by this paper
• Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

  2008cited by this paper
• Decreased survival in EGFR gene amplified vulvar carcinoma.

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Epidermal growth factor receptor mutations in lung cancer

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Inflammatory Myofibroblastic Tumor: Comparison of Clinicopathologic, Histologic, and Immunohistochemical Features Including ALK Expression in Atypical and Aggressive Cases

  2007influential reference
• Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

  2007cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• p16 Overexpression Identifies HPV-positive Vulvar Squamous Cell Carcinomas

  2006cited by this paper
• Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

  2004cited by this paper
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

  2004cited by this paper
• Pathology and genetics of tumours of the lung , pleura, thymus and heart

  2004influential reference
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.

  2002cited by this paper
• Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

  2002cited by this paper
• Anaplastic Lymphoma Kinase Expression in Inflammatory Pseudotumors

  2001influential reference
• p53 Protein expression in squamous cell carcinoma of the vulva

  1999cited by this paper
• Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival.

  1997cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Extrapulmonary Inflammatory Myofibroblastic Tumor (Inflammatory Pseudotumor) A Clinicopathologic and Immunohistochemical Study of 84 Cases

  1995cited by this paper

• Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.

  2022cites this paper
• Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

  2021cites this paper
• Multifocal adenocarcinoma of the lung - EGFR-mutated

  2020cites this paper
• Systemic Therapy in Lung Cancer

  2020cites this paper
• A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology

  2019cites this paper
• EGFR Mutation Analysis in Non-small Cell Lung Carcinoma Patients: A Liquid Biopsy Approach

  2019cites this paper
• Solitary Nodular Invasive Mucinous Adenocarcinoma of the Lung: Imaging Diagnosis Using the Morphologic-Metabolic Dissociation Sign

  2019cites this paper
• Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer

  2019cites this paper
• A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies.

  2019cites this paper
• Stem Cells Treatment to Combat Cancer and Genetic Disease: From Stem Cell Therapy to Gene-Editing Correction

  2018cites this paper
• Abstract. Baicalein, a herbal medicine, is a natural flavonoid isolated from the roots of Scutellaria baicalensis Georgi. It is known for its anticancer, anti-inflammatory and neuropro-

  2017cites this paper
• Baicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis.

  2017cites this paper
• ASK1 (MAP3K5) is transcriptionally upregulated by E2F1 in adipose tissue in obesity, molecularly defining a human dys-metabolic obese phenotype

  2017cites this paper